Walleye Capital LLC Trims Holdings in Abeona Therapeutics Inc (NASDAQ:ABEO)

Walleye Capital LLC cut its position in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 13.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 861,301 shares of the biopharmaceutical company’s stock after selling 129,083 shares during the quarter. Walleye Capital LLC owned approximately 1.99% of Abeona Therapeutics worth $5,443,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ABEO. Rosalind Advisors Inc. boosted its position in Abeona Therapeutics by 4.7% during the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after acquiring an additional 82,000 shares during the last quarter. Citigroup Inc. boosted its holdings in shares of Abeona Therapeutics by 10.1% during the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after purchasing an additional 56,332 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Abeona Therapeutics by 581.6% during the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after purchasing an additional 429,456 shares during the last quarter. Simplify Asset Management Inc. purchased a new stake in shares of Abeona Therapeutics in the second quarter valued at $1,732,000. Finally, abrdn plc increased its stake in Abeona Therapeutics by 158.8% in the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after purchasing an additional 200,647 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on ABEO. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Monday, November 25th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th.

Abeona Therapeutics Stock Performance

Abeona Therapeutics stock opened at $6.39 on Monday. The company has a market cap of $277.77 million, a price-to-earnings ratio of -2.38 and a beta of 1.52. Abeona Therapeutics Inc has a 12 month low of $3.05 and a 12 month high of $9.01. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The stock’s 50-day moving average is $6.26 and its 200-day moving average is $5.35.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.